title: Health related quality of life for men treated for localized prostate cancer with long-term followup.
abstract: OBJECTIVE
  Men who undergo primary treatment for prostate cancer can expect changes in health related quality of life. Long-term changes after treatment are not yet fully understood. We characterized health related quality of life evolution from baseline to 4 years after treatment.
  
  
  METHODS
  We identified 1,269 men in CaPSURE who underwent primary treatment for clinically localized prostate cancer and completed followup health related quality of life questionnaires for at least 4 years. The men underwent radical prostatectomy, external beam radiotherapy, brachytherapy, combined external beam radiotherapy/brachytherapy or androgen deprivation therapy. Health related quality of life was measured using patient reported questionnaires. Effects of select covariates on quality of life were measured with a multivariate mixed model.
  
  
  RESULTS
  Age at diagnosis, time from treatment and primary treatment were significant predictors of health related quality of life in all domains (p <0.05) except primary treatment on sexual bother. Men who underwent radical prostatectomy experienced the most pronounced worsening urinary function but also had the greatest recovery. All treatments worsened urinary bother, and sexual function and bother. All forms of radiotherapy moderately worsened bowel function and bother after treatment but eventual recovery to baseline was noted.
  
  
  CONCLUSIONS
  Age at diagnosis, time from treatment and primary treatment type affect health related quality of life. Treatment has a greater impact on disease specific than general health related quality of life. All treatments adversely affect urinary and sexual function. Most adverse changes develop immediately after treatment. Recovery occurs mostly within 2 years after treatment with little change beyond 3 years.
authors.affiliation: Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
authors.forename: George J
authors.initials: GJ
authors.lastname: Huang
authors.forename: Natalia
authors.initials: N
authors.lastname: Sadetsky
authors.forename: David F
authors.initials: DF
authors.lastname: Penson
mesh_terms: D000368:Aged; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D013997:Time Factors
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2772-80
references.pmid: 15837992
references.citation: Cancer. 2007 Jun 1;109(11):2239-47
references.pmid: 17455209
references.citation: Urology. 1996 Nov;48(5):773-7
references.pmid: 8911524
references.citation: J Gen Intern Med. 2000 Oct;15(10):694-701
references.pmid: 11089712
references.citation: J Urol. 2007 Jan;177(1):273-8; discussion 278-9
references.pmid: 17162062
references.citation: Lancet. 1997 Mar 29;349(9056):906-10
references.pmid: 9093251
references.citation: Health Econ. 1993 Oct;2(3):217-27
references.pmid: 8275167
references.citation: Cancer. 2002 Feb 1;94(3):862-71
references.pmid: 11857323
references.citation: Cancer. 2001 Jun 15;91(12):2302-14
references.pmid: 11413519
references.citation: J Natl Cancer Inst. 2009 Jun 16;101(12):888-92
references.pmid: 19509365
references.citation: J Urol. 2000 Dec;164(6):1973-7
references.pmid: 11061894
references.citation: J Clin Oncol. 2002 Jan 15;20(2):557-66
references.pmid: 11786586
references.citation: Arch Intern Med. 2007 Oct 8;167(18):1944-50
references.pmid: 17923593
references.citation: Int J Urol. 2009 Jan;16(1):45-8
references.pmid: 19120525
references.citation: N Engl J Med. 2008 Mar 20;358(12):1250-61
references.pmid: 18354103
references.citation: J Urol. 2003 Nov;170(5):1822-7
references.pmid: 14532784
references.citation: J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67
references.pmid: 15367568
references.citation: Med Care. 1998 Jul;36(7):1002-12
references.pmid: 9674618
references.citation: JAMA. 1998 Sep 16;280(11):969-74
references.pmid: 9749478
references.citation: N Engl J Med. 2002 Sep 12;347(11):790-6
references.pmid: 12226149
references.citation: J Clin Oncol. 2003 Mar 15;21(6):1147-54
references.pmid: 12637483